Medtronic Exits MiniMed Stake Entirely as Ablation Registry Data and a Pacemaker CE Mark Round Out a Busy October
Published on 10/29/2026 at 14:22 | Editorial boerse-global.de
Medtronic's October news flow ran on two tracks: a clean break from its diabetes legacy and a steady drumbeat of clinical and regulatory wins in cardiac care. The separation from MiniMed Group, Inc. closed on 15 October, and the company confirmed days later that it no longer holds any equity stake in the spun-off business.
The final tally came on 14 October, when Medtronic disclosed the definitive results of its exchange offer. The offer was oversubscribed 5.4 times over. Medtronic swapped its remaining 252,813,348 MiniMed shares and received 55,032,401 of its own ordinary shares in return. With the transaction complete, the company said the split lets it sharpen its focus on cardiovascular medicine, neuroscience and surgery — the three portfolios it now intends to build around.
A CEO Sale Under a Pre-Set Plan
Also dated 15 October was a disclosure that CEO Geoffrey Martha had sold 50,000 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, according to media reports citing a filing with the US Securities and Exchange Commission. Such plans set trading terms in advance, independent of day-to-day developments.
On the market side, the stock was up 1.8% in Monday trading. No link between the gain and the company's scholarship announcement has been established.
Should investors sell immediately? Or is it worth buying Medtronic?
Registry Evidence for Two Ablation Platforms
Five days after the separation closed, Medtronic used the APHRS 2026 specialist congress to present real-world registry data on two of its heart ablation systems. The APEX registry tracked 1,050 patients with atrial fibrillation across 28 sites and covered the Sphere-9 catheter used with the Affera system. Medtronic put the rate of serious complications at 1.1%.
For the PulseSelect PFA system, the company drew on REAL PULSE, a registry of 1,160 patients at 38 sites. Acute treatment success came in at 100%, and the rate of acute serious complications was 0.09%. Both datasets reflect how the systems perform in routine care rather than in controlled trial settings, and Medtronic characterized the findings as positive.
CE Mark for Next-Generation Pacemakers
A separate regulatory milestone landed on 19 October, when Medtronic received CE marking for its Vitalis portfolio of next-generation pacemakers. The devices are designed to stimulate the heart's cardiac conduction system.
Medtronic at a turning point? This analysis reveals what investors need to know now.
Elsewhere, an older product issue resurfaced. The FDA documented a Class II recall of OmniaSecure defibrillation leads on 17 September, covering 717 leads that require technical investigation. The action followed reports of fixation difficulties during implantation, with tissue injury flagged as a possible risk. Medtronic asked customers to set aside affected unused leads and send them back. No patient harm has been reported.
On the community front, the company opened applications for the second round of its Spark Scholarship on Monday. Entries will be accepted through 15 January 2027.
Ad
Medtronic Stock: New Analysis - 29 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
